NCT00541697已完成3 期
A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination Tablets Ezetimibe/Simvastatin (10mg/20mg) and Ezetimibe/Simvastatin (10mg/40mg) Compared to Atorvastatin 20mg in Patients With Type II Diabetes.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 648
- 主要终点
- Determine the additional LDL-C lowering achieved by switching to MK0653A as compared to Atorvastatin after 6 weeks of treatment
研究概览
简要总结
A study to assess the effectiveness and tolerability of MK0653A and MK0653A versus Atorvastatin in lowering LDL-C levels.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Currently being treated with Atorvastatin 10 mg for at least 6 weeks
- •Have Type 2 Diabetes
- •Weight must be stable for more than 6 weeks before entering the study
排除标准
- •Consume more than 14 alcoholic drinks per week.
- •Pregnant or lactating
- •Have taken another investigation drug within 3 months of starting this study
- •History of congestive heart failure, heart attack, coronary artery bypass surgery
- •Uncontrolled high blood pressure
- •HIV positive
- •History of cancer in the last 5 years
结局指标
主要结局
Determine the additional LDL-C lowering achieved by switching to MK0653A as compared to Atorvastatin after 6 weeks of treatment
时间窗: 6 Weeks
次要结局
- Determine the effect of MK0653A versus Atorvastatin on total cholesterol after 6 weeks of treatment(6 Weeks)
研究者
相似试验
已完成
3 期
Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)Atherosclerotic DiseaseCoronary DiseaseHypercholesterolemiaNCT00090168Organon and Co435
已完成
4 期
Double Blind Atorvastatin Amlodipine StudyAnginaNCT00159718Pfizer's Upjohn has merged with Mylan to form Viatris Inc.360
已完成
4 期
A Clinical Trial Study to Evaluate Efficacy and Safety of Atorvastatin in Korean Patients With HypercholesterolemiaHypercholesterolemiaNCT01081548Yonsei University17
已完成
3 期
Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly ControlledDyslipidemiasNCT03482180Kuhnil Pharmaceutical Co., Ltd.215
已完成
2 期
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in HypercholesterolemiaHypercholesterolemiaNCT00690443Aegerion Pharmaceuticals, Inc.44